The ⁢Breakthrough: Revolutionizing Cystic Fibrosis Treatment

Three scientists – Paul Negulescu of Vertex Pharmaceuticals, ‍Jesús (Tito) González (formerly of ‍Vertex), and michael Welsh of the University of Iowa – ⁤have been awarded the ‌2025 Lasker debakey Clinical ⁢Medical Research Award for ⁣their pivotal work in understanding⁤ and treating cystic fibrosis (CF). The $250,000 prize ‍recognizes their contributions to significantly extending⁢ the lifespan and improving‍ the quality ‍of ​life for individuals living ‍with⁣ this deadly genetic disease. Lasker Foundation Proclamation

Cystic fibrosis is caused ⁢by⁤ mutations in the CFTR gene, leading to the buildup of thick ⁤mucus in the lungs, pancreas, and other organs. For decades, treatment focused on managing symptoms. The work ⁤of Negulescu, González, and Welsh shifted the paradigm towards‍ addressing the underlying genetic ‍defect.

Understanding the ‌CFTR ⁤Protein: The Foundation of Treatment

Michael Welsh’s research,beginning in the 1980s,was instrumental in identifying the chloride channel defect caused‍ by the CFTR mutation. He demonstrated that the lack⁤ of​ functional CFTR protein disrupted salt and water balance ‌in the airways, leading to ⁣the characteristic mucus ‍buildup. Welsh’s early research on CFTR

Jesús González, while at Vertex, played a crucial role in developing high-throughput screening methods to identify compounds‍ that could correct‌ the ‌defective CFTR protein. This work​ paved the way for the finding of ivacaftor, the frist CFTR modulator. Vertex Pharmaceuticals History

Paul negulescu ‍led the clinical growth​ of ivacaftor and ​subsequent CFTR ⁤modulators, demonstrating their efficacy and safety ⁣in clinical trials. These modulators‌ don’t cure⁤ CF, but they help the defective protein function more effectively, improving lung function and⁤ overall health. Ivacaftor clinical Trial Results

Impact ‍and Current ⁤Treatments

Before CFTR modulators, the median predicted​ lifespan for individuals with CF was around 30 years. Today, with access to‌ these therapies, many individuals with CF can live well into their 40s ‍and beyond. The impact is particularly notable for ⁢those with specific CFTR mutations that respond well to the available modulators.

Currently,several CFTR‌ modulators are available,including⁤ ivacaftor (Kalydeco),lumacaftor/ivacaftor (Orkambi),tezacaftor/ivacaftor (Symdeko),and ‌elexacaftor/tezacaftor/ivacaftor (Trikafta). Trikafta,⁤ approved by⁤ the FDA ⁤in 2019, is effective for approximately 90% of people with CF. Cystic Fibrosis Foundation – Treatments